

IAP4 Reg'd PCT Entry

Approved for use through 07/31/2006. OMB 0651-0031
U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office
Under the Paperwork Reduction Act of 1995, respondents are required to respond to a collection of information that is approved by the Office of Management and Budget (OMB) control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/539,093 (Conf. #9226)
Filing Date	15 June 2005
First Named Inventor	John M. YANNI
Art Unit	10/539093
Examiner Name	
Attorney Docket Number	2394 US F

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	26 References and Return Card.
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
<input type="checkbox"/> Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Alcon Research, Ltd.		
Signature			
Printed name	Teresa J. Schultz		
Date	9 Dec. 2005	Reg. No.	40,526

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Barbara McKenzie	Date	9 December 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John M. YANNI

Serial No: 10/539,093 (Conf. #9226)

Filed: 15 June 2005

Examiner:

Group Art Unit:

FOR: TREATMENT OF DRY EYE BY RESTORING 15-LIPOXYGENASE ACTIVITY TO
OCULAR SURFACE CELLS

**INFORMATION DISCLOSURE STATEMENT PURSUANT
TO 37 C.F.R. 1.56, 1.97, AND 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2), copies of the U.S. patents are not enclosed.

A copy of the International Search Report issued in the PCT application, of which the present application is a 35 U.S.C. §371 application, is also included for the Examiner's convenience.


Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

9 Dec. 2005
Date

By: Teresa J. Schultz
Teresa J. Schultz
Registration No. 40,256
(817) 551-4231

Address for Correspondence:
Alcon Research, Ltd.
Attn: Teresa J. Schultz
6201 S. Freeway, Mail Code Q-148
Fort Worth, TX 76134-2099
Attorney Docket No.: 2394 US F



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/539,093
Filing Date	15 June 2005
First Named Inventor	John M. YANNI
Art Unit	
Examiner Name	
Attorney Docket Number	2394 US F

Sheet 1 of 5

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US- 3,991,759	11-16-1976	Urquhart	
	A2	US- 4,131,651	12-26-1978	Shah et al.	
	A3	US- 4,370,325	01-25-1983	Packman	
	A4	US- 4,409,205	10-11-1983	Shively	
	A5	US- 4,744,980	05-17-1988	Holly	
	A6	US- 4,753,945	06-28-1988	Gilbard et al.	
	A7	US- 4,818,537	04-04-1989	Guo	
	A8	US- 4,868,154	09-19-1989	Holly	
	A9	US- 4,914,088	04-03-1990	Glonek et al.	
	A10	US- 4,966,773	10-30-1990	Gressel et al.	
	A11	US- 5,041,434	08-20-1991	Lubkin	
	A12	US- 5,075,104	12-24-1991	Gressel et al.	
	A13	US- 5,174,988	12-29-1992	Mautone et al.	
	A14	US- 5,278,151	01-11-1994	Korb et al.	
	A15	US- 5,290,572	03-01-1994	MacKeen	
	A16	US- 5,294,607	03-15-1994	Glonek et al.	
	A17	US- 5,371,108	12-06-1994	Korb et al.	
	A18	US- 5,403,841	04-04-1995	Lang et al.	
	A19	US- 5,455,265	10-03-1995	Chandraratna	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	A20					
	A21					
	A22					
	A23					
	A24					
	A25					

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Project Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet

2

of

5

10/539.093

15 June 2005

John M. YANNI

Examiner Name


Attorney Docket Number

2394 US F

[illegible][illegible]Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/539,093
Filing Date	15 June 2005
First Named Inventor	John M. YANNI
Art Unit	
Examiner Name	
Attorney Docket Number	2394 US F

Sheet 3 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	BARABINO S and DANA MR (2004). Animal models of dry eye: a critical assessment of opportunities and limitations. 45(6): 1641-1646	
	B2	BEHRENS et al. (2002). Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. IOVS 43(4): 968-977	
	B3	BRASH et al., "Discovery of a second 15S-lipoxygenase in humans", PROC. NATL. ACAD. SCI. USA 94:6148-6152 (1997)	
	B4	DARTT et. al., "Vasoactive Intestinal Peptide-Stimulated Glycoconjugate Secretion from Conjunctival Goblet Cells", EXPERIMENTAL EYE RESEARCH 63:27-33, (1996)	
	B5	DILLY et al., "Surface changes in the anaesthetic conjunctiva in man, with special reference to the production of mucus from a non-goblet-cell source", BRITISH JOURNAL OF OPHTHALMOLOGY 65:833-842 (1981).	
	B6	GREINER et al., "Mucus Secretory Vesicles in Conjunctival Epithelial Cells of Wearers of Contact Lenses", ARCHIVES OF OPHTHALMOLOGY 98:1843-1846 (1980)	
	B7	HSI et al., "Evaluation of the activity and localization of 15-Lipoxygenase-1 after introduction into human colorectal carcinoma Caco-2 cells", PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS 64 (4 & 5):217-225 (2001)	
	B8	HSI et al., "Opposing Effects of 15-Lipoxygenase-1 and -2 Metabolites on MAPK Signaling in Prostate", THE JOURNAL OF BIOLOGICAL CHEMISTRY 277(43):40549-40556 (2002)	
	B9	International Search Report for PCT/US03/33139 [#2394 WO F]	
	B10	KAMATA et al. (2001). Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. MOLECULAR THERAPY 4(4): 307-312	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/539,093		
		Filing Date	15 June 2005		
		First Named Inventor	John M. YANNI		
		Art Unit			
Examiner Name					
Sheet	4	of	5	Attorney Docket Number	2394 US F

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	LEMP, "Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes", The CLAO Journal, 21(4):221-232 (1995)	
	C2	LIMINGA et al (1994). Arachidonate 15-lipoxygenase in human corneal epithelium and 12- and 15-lipoxygenases in bovine corneal epithelium: comparison with other bovine 12-lipoxygenases. Biochim Biophys Acta. 1210(3): 288-296	
	C3	LIMINGA and OLIW, "Qualitative and Quantitative Analysis of Lipoxygenase Products in Bovine Corneal Epithelium by Liquid Chromatography-Mass Spectrometry with an Ion Trap", LIPIDS 35 (2):225-232 (2000)	
	C4	MAROM et al., "Human Airway Monohydroxyeicosatetraenoic Acid Generation and Mucus Release", JOURNAL OF CLINICAL INVESTIGATION 72:122-127 (1983)	
	C5	MARTIN et al. (2002). Gene delivery to the eye using adeno-associated viral vectors, METHODS 28 267-275	
	C6	MCCULLEY and SHINE, "Tear Film Structure and Dry Eye", Contactologia, 20(4):145-49 (1998)	
	C7	NAKMURA et. al., "Gefarnate Stimulates Secretion of Mucin-Like Glycoproteins by Corneal Epithelium in Vitro and Protects Corneal Epithelium from Desiccation in Vivo", EXPERIMENTAL EYE RESEARCH 65:569-574 (1997)	
	C8	PETERSON CM et al. (2002). Dry eye syndrome in postmenopausal women. JAMA 287(5): 585-586	
	C9	PFEIFER A and VERMA IM (2001). Gene Therapy: promises and problems. Annu Rev Genomics Hum Genet. 2: 177-211	
	C10	SHAPPELL et al., "15-Lipoxygenase-2 (15-LOX-2) Is Expressed in Benign Prostatic Epithelium and Reduced in Prostate Adenocarcinoma", AMER. J. PATH. 155(1):235-245 (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/539,093
Filing Date	15 June 2005
First Named Inventor	John M. YANNI
Art Unit	
Examiner Name	
Attorney Docket Number	2394 US F

Sheet

5

of

5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D1	SHAPPELL et al., "15-Lipoxygenase-2 Expression in Benign and Neoplastic Sebaceous Glands and Other Cutaneous Adnexa", J. INVESTIGATIVE DERMATOLOGY. 117(1):36-43 (2001)	
	D2	SHINE and MCCULLEY, "Keratoconjunctivitis Sicca Associated With Meibomian Secretion Polar Lipid Abnormality", ARCHIVES OF OPHTHALMOLOGY 116(7):849-52 (1998)	
	D3	STECHSCHULTE et al., "Rapid Ocular Angiogenic Control via Naked DNA Delivery to Cornea", INVEST. OPHTHALMOL. VIS. SCI. 42(9):1975-1979 (2001)	
	D4	VERMA, I. M. and SOMIA, N. (1997). Gene therapy-promises, problems and prospects. NATURE 389: 239-242	
	D5	WATANABE et al., "Human Corneal and Conjunctival Epithelia Produce a Mucin-like Glycoprotein for the Apical Surface", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE 36(2):337-344 (1995)	
	D6	YANNI et al., "Effect of Intravenously Administered Lipoxigenase Metabolites on Rat Tracheal Mucous Gel Layer Thickness", INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY 90:307-309 (1989)	
	D7		
	D8		
	D9		
	D10		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.